Abstract Defects in HLA class I antigen processing machinery (APM) component expression often have a negative impact on the clinical course of tumors and on the response to T cell-based immunotherapy. Since only scant information is available about the frequency and clinical signiWcance of HLA class I APM component abnormalities in prostate cancer, the APM component expression pattern was analyzed in 59 primary prostate carcinoma, adjacent normal tissues, as well as in prostate carcinoma cell lines. The IFN-inducible proteasome subunits LMP2 and LMP7, TAP1, TAP2, calnexin, calreticulin, ERp57, and tapasin are strongly expressed in the cytoplasm of normal prostate cells, whereas HLA class I heavy chain (HC) and 2 -microglobulin are expressed on the cell surface. Most of the APM components were downregulated in a substantial number of prostate cancers. With the exception of HLA class I HC, TAP2 and ERp57 not detectable in about 0.5% of tumor lesions, all other APM components were not detected in at least 21% of lesions analyzed. These APM component defects were associated with a higher Gleason grade of tumors and an early disease recurrence. Prostate carcinoma cell lines also exhibit a heterogeneous, but reduced constitutive APM component expression pattern associated with lack or reduced HLA class I surface antigens, which could be upregulated by IFN-. Our results suggest that HLA class I APM component abnormalities are mainly due to regulatory mechanisms, play a role in the clinical course of prostate cancer and on the outcome of T cell-based immunotherapies.
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Introduction
Prostate cancer (PC), a complex heterogeneous disease with a variable clinical course, is the most common cancer in the United States and in Western countries. It accounts for 33% of cancer cases and about 9% of cancer-related deaths among men [1, 2] . Initially most PC patients can be eVectively treated with surgery, radiation, and androgen deprivation, but a large percentage of men require additional therapy due to the high frequency of recurrence of the disease. Due to its low growth rate coupled with a signiWcantly variable presentation it is diYcult or even impossible to conclusively determine, which treatment modality is the best for a patient. Currently ongoing clinical trials provide promise for the implementation of immunotherapy for the treatment of PC [3] and a number of immunotherapeutic strategies alone or in combination with radiation or chemotherapy have been explored [4, 5] . They target the prostate-speciWc antigen (PSA), other prostate-associated antigens or block the coinhibitory receptor CTLA4 in order to enhance PC antigen-speciWc immune responses [3, [6] [7] [8] [9] [10] [11] . These studies demonstrated that immune-based therapies are safe, feasible, and exhibit some clinical beneWt in PC patients. There exists evidence for improved responses at earlier disease stages. Activated eVector CD8 + T cells, but also tumor antigen (TA)-speciWc T cells could be induced, although it still has to be deWned, whether these PC antigen-speciWc immune responses have clinical relevance [6, 9, [12] [13] [14] .
The recently described positive outcome of a clinical trial with T cell-based immunotherapy in PC has stimulated interest in the characterization of the antigen processing machinery (APM) component expression in PC lesions, since this machinery plays a crucial role in the generation and expression of the trimeric HLA class I surface antigen complex on tumor cells. This complex, which mediates the interaction of tumor cells with HLA class I antigenrestricted, TA-speciWc cytotoxic T lymphocytes (CTL), is generated through several steps with the participation of diVerent molecules. SpeciWcally, 9-11 amino acid long peptides are derived from the cleavage of mostly, although non-exclusively, endogenous cytosolic and nuclear proteins by the constitutive and interferon (IFN)-inducible proteasome subunits as well as by other aminopeptidases [15] . Peptides are then translocated via the heterodimeric transporter associated with antigen processing (TAP) complex from the cytosol into the endoplasmic reticulum (ER), where they are loaded with the help of the chaperones calnexin, calreticulin, ERp57, and tapasin (tpn) onto 2 -microglobulin ( 2 -m)-HLA class I heavy chain (HC) complexes. The assembled trimeric HLA class I-peptide complex is released from the peptide-loading complex and transported via the trans-Golgi apparatus to the cell surface for presentation to CD8 + CTL [16] . Defects in APM component expression have been described in several types of malignant diseases [reviewed by [17] [18] [19] [20] . They appear to have clinical relevance, since they can be associated in some tumors with tumor progression, metastases formation as well as poor patients' survival. To the best of our knowledge, only limited information is available about the MHC class I APM component expression in murine and human PC cells and its impact on immune responses [21] [22] [23] [24] . Murine primary and metastatic prostate cancer cell lines express MHC class I surface antigens despite the lack of detectable LMP2, LMP7, TAP1, and TAP2 transcription; IFN-treatment induced these four APM components and enhanced MHC class I surface expression [22] . The TAP defect in the murine metastatic PC cell line is caused by impaired initiation of TAP1 transcription [24] . In particular, Sanda et al. [21] determined the constitutive and IFN--induced transcription of TAP2, 2 -m and HLA class I HC as well as the HLA class I surface antigen expression in Wve human PC cell lines. Lack of TAP2 expression in one metastatic human prostate cancer cell line resulted in loss of HLA class I antigen expression, which could be restored by IFN-. Two of the Wve analyzed PC cell lines did not express HLA class I antigens due to defects in their assembly or impaired histone acetylation [21] thereby escaping from T cell recognition. Similar defects were found in surgically removed PC lesions. Immunohistochemical staining of benign hyperplastic, primary and/or metastatic PC lesions with HLA class I-and/or 2 -m-speciWc monoclonal antibodies (mAb) demonstrated a downregulation of these molecules in a high percentage of PC lesions [25] . To the best of our knowledge, the expression of HLA class I APM components in human PC lesions has not yet been investigated in detail. Since this information contributes to our understanding of the molecular mechanisms underlying defects in the presentation of PC antigen-derived peptides to CTL, we have analyzed in this study the expression of HLA class I APM components in 59 formalin-Wxed, paraYn-embedded primary PC lesions. Furthermore, we have analyzed the modulation of APM component expression by IFN-in four established human PC cell lines with a phenotype similar to that found in surgically removed lesions to determine whether the defects observed are caused by regulatory rather than structural abnormalities. Finally, to assess the clinical signiWcance of our Wndings, we have correlated the results of immunohistochemical staining with the histopathological characteristics of the lesions and with disease progression.
Materials and methods

Patients and tissue samples
The tissue samples analyzed included 59 archival formalinWxed, paraYn-embedded primary PC lesions and corresponding normal prostate tissues from patients with a mean age of 63 years (49-75). All patients had been treated with an endoscopic extra peritoneal radical prostatectomy [26] and were R0-resected. The tumors analyzed were diagnosed according to the WHO classiWcation of tumors [1] and staged according to the tumor-node-metastases system [27] . The mean follow-up was 71 months (6-144). The clinico-pathological characteristics of the PC lesions are summarized in Table 1 . Informed consent for this study was obtained from all patients. A tissue microarray (TMA) containing 59 1.5 mm large tissue cores was constructed as described [28, 29] . The TMA included 19 cases with PSA recurrence deWned as detectable serum PSA (¸0.2 ng/ml) within 3 years following radical prostatectomy and 37 cases without PSA recurrence within 5 years. The two groups of patients did not signiWcantly diVer in their clinico-pathological characteristics. No data concerning recurrence were available for three patients.
Cell lines and cytokine treatment
The human PC cell lines LNCaP, 22RVI, PC3, and DU145, all purchased from American Tissue Culture Collection (ATCC), Manassas, VA, were cultured in phenol red-free RPMI1640 medium (PAA Laboratories, Pasching, Austria) supplemented with 2 mM L-glutamine (Cambrex Bio Science, Verviers, Belgium), 7.5 mM HEPES (CC pro, Oberdorla, Germany), 10% fetal calf serum (FCS) (Invitrogen, Carlsbad, CA), 100 g/ml penicillin and 100 g/ml streptomycin (PAA Laboratories).
Cytokines
Human recombinant IFN-and tumor necrosis factor (TNF)-was purchased from Pan Biotech, Aidenbach, Germany.
Monoclonal and polyclonal antibodies
The mouse monoclonal antibody (mAb) HC-10, which recognizes 2 -m-free HLA-A3, -A10, -A28, -A29, -A30, -A31, -A32, -A33, and -B (excluding -B5702, -B5804, and -B73) HC [30, 31] ; the 2 -m-speciWc mAb L368 [32] ; the low molecular weight polypeptide (LMP) 2-speciWc mAb SY-1 [32] , the LMP7-speciWc mAb HB2 [33] ; the TAP1-speciWc mAb NOB-1 [34] , the TAP2-speciWc mAb NOB-2 [34] , the calnexin-speciWc mAb TO-5 [35] ; the calreticulinspeciWc mAb TO-11 [35] ; the ERp57-speciWc mAb TO-2 [35] and the tpn-speciWc mAb TO-3 [36] were developed and characterized as described. All the above-mentioned mAb are IgG1 except mAb HC-10, which is an IgG2a. mAb were puriWed from ascitic Xuid by sequential precipitation with ammonium sulfate and caprylic acid [36] . The purity of the mAb preparations was assessed by SDS-PAGE. The activity of the mAb preparations was monitored by testing lymphoid cell lysates in Western blot. The combined mouse/rabbit "Envision and Dual Link System HRP detection" was purchased from Dako (Hamburg, Germany). The FITC-labeled HLA class I-speciWc mAb B9.12.5 and the FITC-labeled lgG2a mAb used for Xow cytometric analyses were purchased from Beckman Coulter (Krefeld, Germany).
Semi-quantitative and quantitative RT-PCR analysis
Total cellular RNA was extracted from cells using the RNeasy Mini Kit (Qiagen, Hilden, Germany) followed by digestion with DNase I (Invitrogen) according to the manufacturer's instructions. cDNA was synthesized from 500 ng of total RNA using the RevertAid TM H Minus First Strand cDNA Synthesis Kit (Fermentas, St. Leon-Rot, Germany) as described in the manufacturer's instructions.
The target-speciWc primers and conditions used for semiquantitative and quantitative RT-PCR are summarized in Table 2 . Semi-quantitative RT-PCR was performed as recently described [37] . Comparative quantiWcation of gene expression was performed by real-time PCR on a Rotor Gene 2000 (Corbett Research, Sydney, Australia) using the quantitative Platinum ® SYBR green qPCR SuperMix-UDG (Invitrogen). AmpliWcations were carried out by an initial n.a. 4
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n.a. 3 n number of samples analyzed, n.a. not analyzed hold at 50°C for 2 min followed by denaturation at 95°C for 2 min. After 40 cycles with denaturation at 95°C for 15 s and annealing between 58°C and 60°C for 30 s the melting steps were performed starting at 60°C rising up to 99°C with 1°C at each step. The melting curve analysis was provided at the end of each run to control PCR speciWcity. Results of the qRT-PCR data are presented as relative mRNA expression quantiWed with the Rotor Gene analysis software and normalized to -actin transcription levels.
Immunohistochemistry
Immunohistochemical staining of formalin-Wxed, paraYnembedded tissues was performed as recently described [38] . After staining, all slides were reviewed by one surgical pathologist (AH) without knowledge of the clinical data. Results were scored as negative (0), heterogeneous (1) and positive (2) , when the percentage of stained tumor cells was <25, between 25 and 75, and >75, respectively. Adjacent normal prostate epithelium served as a control. In addition, the staining intensity was scored as 0 (negative), 1 (weak), 2 (moderate) and 3 (strong). The results were then analyzed according to Armes et al. [39] : a combined score was derived by adding the two scores, i.e. % of stained tumor cells and staining intensity. Combined scores of "0" were designed as negative, "1-2" as weak expression, "3-4" as moderate expression, and "5" as strong expression. Negative controls were performed by omitting primary antibodies.
Flow cytometry
Cells were stained with a FITC-labeled HLA class I-speciWc mAb (Beckman Coulter) using a FITC-labeled lgG2a mAb (Beckman Coulter) as control [40] . Stained cells were analyzed with a Xuorescence activated cell sorter (Beckmann & Coulter, Krefeld, Germany). The results are expressed as mean Xuorescence intensity (MFI) + SD of the MFI values obtained in three independent experiments.
Statistical analysis
The results of immunohistochemical staining were correlated with the histopathological characteristics of the PC lesions and with the clinical characteristics of the patients utilizing 2 -test (Fisher exact test, two-sided). p values <0.05 were considered to be signiWcant. Statistical analyses were performed utilizing the Statistical Package for the Social Sciences (SPSS) version 13.0 (SPSS, Chicago, IL, USA).
Results
HLA class I APM component expression in normal prostate tissue
A TMA comprising 59 PC specimens and corresponding normal prostate tissue was stained with LMP2-, LMP7-, To determine whether HLA class I APM component downregulation or loss is associated with disease progression, the immunohistochemical data obtained from the analysis of 59 primary PC lesions were correlated with tumor grading, staging, as well as PSA recurrence. Complete loss or weak expression of calnexin was associated with an early recurrence (p = 0.003) and an aggressive tumor phenotype (Gleason score¸7, p = 0.002). In addition, lack of cytoplasmic and membranous staining by the mAb HC-10 was correlated with early tumor recurrence (p = 0.03). Finally, a synchronous downregulation of at least seven APM components was found in 41% of PC patients with early recurrence, but in only 24% of the patients without recurrence.
Heterogeneous constitutive and IFN--inducible HLA class I APM component expression in PC cell lines
To get insight into the mechanisms underlying HLA class I APM abnormalities in PC lesions, four PC cell lines (LNCaP, PC3, 22RVI, and DU145) were analyzed for their constitutive and IFN--inducible HLA class I APM component and HLA class I surface antigen expression. As representatively shown in Fig. 3a , the level of HLA class I APM component mRNA was in general low in the PC cell lines analyzed, although the extent of downregulation varied among the APM components. In particular, the mRNA level of TAP2 was lower in LNCaP and 22RVI cells than in PC3 and DU145 cells. As shown by qRT-PCR in PC3 and DU145 cells, the expression of most APM molecules was upregulated by IFN- (Fig. 3b) , whereas LNCaP and 22RVI cells were not IFN-responsive; this change was associated with an increased HLA class I surface antigen expression in PC3 and DU145 cells, but not in the two other PC cell lines (Fig. 3c) . The low APM component expression was accompanied by the lack or low expression of HLA class I antigens on all PC cell lines (Fig. 3c) . These data suggest that the reduced HLA class I APM component expression in PC3 and DU145 cells was mainly due to their dysregulation rather than structural alterations of the APM molecules. In contrast neither APM components nor HLA class I antigens were upregulated by incubating LNCaP and 22RVI cells with IFN- (Fig. 3a) . The resistance of both PC cell lines to IFNtreatment was not due to impaired expression of the IFNreceptors (data not shown). The impaired restoration of APM component expression by IFN-in LNCaP and 22RVI cells points to defects in the IFN signal transduction pathway in these cell lines since 10 ng/ml TNF-was able to enhance APM component expression (data not shown).
Discussion
Immunohistochemical staining of a TMA comprising 59 primary PC lesions and autologous normal tissues has shown downregulation of all the HLA class I APM components analyzed, although with a diVerent frequency in tumor lesions when compared to normal prostate tissues. A key Wnding of this study was the frequent loss or downregulation of calnexin and/or tpn, which appears to be an independent prognostic marker of tumor recurrence (Fig. 1) . In contrast, HLA class I HC expression levels were less aVected in primary PC lesions; the frequency of downregulation described in this manuscript is markedly lower than that reported by other authors [25, 41] in a large number of PC lesions and that reported in other tumor types, e.g. melanoma and colon carcinoma [19, 20, 44, 45] . In contrast a high frequency of loss or downregulation of LMP2, TAP1, and tpn as well as of 2 -m was demonstrated in PC lesions when compared to normal prostate tissue. The frequency of LMP2, TAP1, and tpn downregulation is higher than that found in lung, colorectal, hepatocellular, cervical, and renal cell carcinoma (RCC) [19, 20, 38, 46] . In parallel to the Wndings in head and neck squamous cell carcinoma, cervical carcinoma, esophageal carcinoma, breast carcinoma, and melanoma the impaired TAP expression in PC cancer lesions is associated with tumor grading, staging, and time to recurrence [47] [48] [49] [50] . In this context it is noteworthy that the HC10 antibody used for immunohistochemical analysis of the TMA only recognizes free HLA class I HC, but not HLA class I surface expression. This is based on the fact that the TMA represents paraYn-embedded This might explain the diVerence in the frequency of HLA class I abnormalities in prostate cancer, which has been reported to occur in approximately 80% PC lesions [41] . However, APM defects have been shown to be directly associated with reduced or impaired HLA class I surface expression, since the generation and supply of antigenic peptides is not suYcient for proper HLA class I antigen presentation.
In the present study we show a correlation of the HLA class I APM defects with clinical parameters in PC. The disease recurrence as well as biological aggressiveness of the tumor determined by high Gleason scores was associated with loss and/or downregulation of selected HLA class I APM components, e.g. calnexin and tpn. If independently conWrmed in a larger number of patients, these data argue in favor of the possibility that the evaluation of the structural integrity and expression pattern of these molecules might be helpful to optimize the selection of PC patients to be treated with T cell-based immunotherapy.
The molecular events causing HLA class I APM component abnormalities could either reXect structural alterations in these molecules, in particular haplotype, locus, or allelespeciWc loss of HLA class I HC, mutations or deletions in 2 -m, defects in the IFN signal transduction pathway, or deregulation of APM components occurring at the transcriptional, posttranscriptional, or epigenetic level. Deregulation of APM components and the IFN-signal transduction cascade is suggested by our results analyzing the constitutive and IFN--inducible APM component and HLA class I surface antigen expression in the PC cell lines LNCaP, 22RVI, PC3, and DU145. The PC3 and DU145 cells express higher levels of APM components than the LNCaP and 22RVI. Furthermore, in PC3 and DU145 cells, but not in LNCaP and 22RVI cells, the impaired APM component and HLA class I antigen surface expression was upregulated by IFN- (Fig. 3b) . However, the resistance of LNCaP and 22RVI to IFN-was not due to defects in the IFN-receptor (data not shown). It is noteworthy, that also IFN-and IFN-does not upregulate HLA class I APM components in these cells, whereas TNF-treatment caused an increased HLA class I surface antigen expression. Thus, the reduced APM component expression in LNCaP and 22RVI cells appears not to be caused by structural alterations, but might be due to their dysregulation. However, we could not exclude epigenetic mechanisms, since HLA class I downregulation in LNCaP cells has been demonstrated to be associated with an altered acetylation status of the 2 -m promoter, which could be corrected by trichostatin A [25] .
The LMP2 and LMP7 expression in normal prostate tissues is a primarily unexpected Wnding since these immunoproteasome subunits are generally only expressed in cells upon IFN-treatment. This Wnding might reXect either a tissue-speciWc regulation controlled by the microenvironment or undetected pathological processes. Whatever the mechanism, LMP2 and LMP7 appear to be coordinately downregulated in prostate cancer cells. In addition, LMP2 and TAP1 loss or downregulation in prostate cancer lesions is coregulated in about 17 and 59% of cases, respectively, due to their regulation by the bi-directional LMP2/TAP1 promoter [51] . So far, the expression of the chaperones calnexin and calrecticulin has been analyzed only in a few types of human tumors. In cervical cancer, calnexin and calreticulin expression was not impaired [50] , whereas in laryngeal carcinoma both chaperones were downregulated in 25% of the lesions analyzed. In contrast, a frequent downregulation or loss of calnexin and calreticulin was found in PC lesions (Fig. 1b) . Recently it has been described that ERp57 expression constitutes a negative prognostic marker in some neoplasia including gastric cancer [52] . Furthermore the inability of calreticulin to be presented on the cell surface may lead in tumor cells to elicit a proper immune response [53, 54] , which might be also associated with chemotherapy resistance [55] . These data suggest that in particular calreticulin is involved in HLA class I antigen stabilization and assembly and thus may be essential for HLA class I surface antigen expression. Thus, deWciencies in the function of chaperones might aVect the eYcacy of peptide loading and presentation onto HLA class I molecules, but their role in PC development and progression has still to be deWned.
